Ronald Kershner, Ph.D. Named Vice President, Biostatistics and Data Operations at Premier Research Group
News May 18, 2011
Premier Research Group Limited announces the appointment of Ronald Kershner, PhD to the position of Vice President, Biostatistics and Data Operations for North America.
Ron brings a strong background in biostatistics and data management with more than 25 years of experience in all operational aspects of clinical trial planning, execution and delivery within the pharmaceutical, biotechnology and contract research industries. Ron has worked on more than 24 NDAs in various therapeutic areas and has served on over 20 Data Monitoring Committees.
Ron holds a Ph.D. in Statistics from Cornell University and has authored more than 30 publications and presentations with a recent focus on eClinical technologies and independent data monitoring committees.
He has been an invited speaker at multiple conferences and symposia including DIA, Eastern Technology Council, Clinical Trials Congress and the American Society of Transplant Physicians.
Ron is currently a speaker on the faculty series for Society of Clinical Research Associates speaking on the role of the data monitoring committee (DMC). He has served on Steering Committees of the PMA and has been a past member of the Regional Advisory Board of the Biometrics Society.
Ron joins us from Novella Clinical; in addition, he has held positions at AAIPharma, inVentiv Clinical Solutions and Omnicare Research.
“We are very pleased to welcome Ron to Premier Research to manage these key operational groups. He has a significant track record with developing efficient and productive teams producing high-quality, on-time deliverables for sponsors as well as providing strategic consulting services for biostatistical study design and guidance for all phases of clinical trials ,” said Krista Armstrong, PhD, Vice President, North America. “His extensive experience leading biometrics teams makes him a natural fit for our company.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE